Interplay of a well‐known medication and newly discovered transporters driving bacteria‐induced inflammation in psoriasis

SLC46A2 is crucial for the transportation of DAP-muropeptides into the cytosol, leading to NOD1 activation. Subsequent neutrophil recruitment through the release of IL-1α proves to be critical for the progression of psoriatic inflammation. The commonly prescribed anti-inflammatory drug methotrexate inhibits Slc46a2-mediated DAP-muropeptide transport in the mouse model, suggesting a therapeutic mechanism for suppressing psoriatic inflammation. C. accolens; Corynebacterium accolens; DAP, diaminopimelic acid; IMQ, imiquimod; MTX, methotrexate; Nod, nucleotide-binding and oligomerization domain; ns, not stimulated; SLC46, solute carrier family 46 The author declares no conflict of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.